The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of ERK inhibitor JSI-1187 for patients with advanced solid tumors with MAPK pathway mutations.
 
yuqin xi
Employment - JS InnoPharm
 
Zhenghang Wang
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Yu Chen
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Mei Li
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Linda J. Paradiso
No Relationships to Disclose
 
Thomas J. Myers
No Relationships to Disclose
 
Junqiang He
Employment - JS innopharm(shanghai) Ltd
 
Jintao Zhang
Employment - JS InnoPharm
Leadership - JS InnoPharm
Stock and Other Ownership Interests - JS InnoPharm
 
Wen Xu
Employment - JS innopharm(shanghai) Ltd
Leadership - JS innopharm(shanghai) Ltd
 
Lei Zhang
Employment - JS innopharm(shanghai) Ltd
Leadership - JS innopharm(shanghai) Ltd
 
Ao Li
Employment - JS innopharm(shanghai) Ltd